VivoSim Labs, INC.

Listed Company

VIVSCIK 0001497253NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Mar 31

Period

FY 2025

Revenue

$144.0K

Net Income

$-2.49M

Total Assets

$14.65M

Equity

$10.49M

Shares Out

2.61M

Op. Cash Flow

$-9.50M

Business

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that provides testing of drugs and drug candidates in three-dimensional human tissue models. It offers liver and intestinal toxicology predictive screening, investigational toxicology, mechanism-of-action studies, bespoke research services, and internal early-stage drug discovery using proprietary 3D bioprinting and cell-culture technologies. The company operates a platform business with capabilities in bioprinted tissues, organoids, high-throughput systems, and a portfolio of patented bioprinting and tissue constructs. Its services are provided to pharmaceutical and biotech companies across global markets through direct service engagements and collaborations.

Summary from filing dated 2025-06-05

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31
Total Revenues	144,000	109,000	370,000	2	0
Cost of revenues	5,000	—	—	—	0
Research and development expenses	5	5	9	3	1
Selling, general, and administrative expenses	8	10	9	10	16
Total costs and expenses	13	15	18	13	17
Loss from Operations	−13	−15	−18	−11	−17
Gain on investment in equity securities	0	12,000	29,000	0	—
Gain on sale of asset	10	—	—	—	—
Interest income	140,000	405,000	454,000	8,000	15,000
Interest expense	−10,000	—	—	—	—
Total Other Income	10	417,000	474,000	33,000	2,000
Income Tax Expense	−2,000	−2,000	−2,000	−2,000	−2,000
Net Loss	−2	−15	−17	−11	−17
Unrealized loss on available-for-sale debt securities	0	−2,000	2,000	0	—
Comprehensive Loss	−2	−15	−17	−11	−17
Net loss per common share basic	−1.7	−19.25	−1.98	−1.32	—
Net loss per common share diluted	−1.7	−19.25	−1.98	−1.32	—
Weighted average shares used in computing net loss per common share basic	1	762,076	9	9	—
Weighted average shares used in computing net loss per common share diluted	1	762,076	9	9	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-03-31	FY 2024 2024-12-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Cash and cash equivalents	11	—	3	15	29
Accounts receivable	30,000	—	33,000	152,000	0
Inventory	0	—	297,000	0	—
Prepaid expenses and other current assets	800,000	—	700,000	889,000	858,000
Total current assets	12	—	4	17	30
Fixed assets, net	419,000	—	669,000	902,000	662,000
Restricted cash	100,000	—	143,000	143,000	143,000
Operating lease right-of-use assets	867,000	—	1	2	2
Escrow receivable	1	—	—	—	—
Prepaid expenses and other assets, net	90,000	—	302,000	515,000	805,000
Total assets	15	—	6	20	33
Accounts payable	2	—	627,000	331,000	415,000
Accrued expenses	1	—	727,000	3	489,000
Insurance premium financing liability	100,000	—	—	—	—
Liability to be settled in equity	218,000	—	—	—	—
Operating lease liability, current portion	521,000	—	506,000	492,000	479,000
Total current liabilities	4	—	2	4	1
Operating lease liability, net of current portion	421,000	—	888,000	1	2
Total liabilities	4	—	3	5	3
Commitments and Contingencies (Note 9)	—	—	—	—	—
Common stock, $0.001 par value; 200,000,000 shares authorized, 1,898,068 and 839,814 shares issued and outstanding at March 31, 2025 and 2024, respectively	2,000	—	1,000	9,000	9,000
Additional paid-in capital	353	—	343	340	338
Accumulated deficit	−342	—	−340	−325	−308
Treasury stock, 3 shares at cost	−1,000	—	−1,000	−1,000	−1,000
Total stockholders' equity	10	364,000	4	15	30
Total Liabilities and Stockholders' Equity	15	—	6	20	33

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31
Gain on sale of asset	−10	0	—	—	—
Accretion on investments	−38,000	−142,000	−105,000	0	—
Depreciation and amortization	266,000	280,000	293,000	142,000	41,000
Stock-based compensation	532,000	2	2	2	6
Non-cash lease expense	432,000	406,000	—	—	—
Inventory write-off	798,000	0	—	—	0
Accounts receivable	3,000	119,000	−152,000	0	111,000
Inventory	−501,000	−297,000	0	—	0
Prepaid expenses and other assets	253,000	392,000	177,000	384,000	−1
Accounts payable	1	296,000	−148,000	134,000	−439,000
Accrued expenses	717,000	−2	2	49,000	−650,000
Operating lease liability	−452,000	−411,000	70,000	30,000	0
Net cash used in operating activities	−10	−15	−12	−8	−13
Purchases of fixed assets	−13,000	−42,000	−396,000	−409,000	−405,000
Proceeds from sale of asset	9	0	—	—	—
Purchases of investments	−3	−11	−10	0	—
Maturities of investments	3	11	10	0	—
Liquidation of equity securities	0	718,000	0	—	—
Net cash provided by investing activities	9	816,000	−966,000	−409,000	−393,000
Proceeds from issuance of common stock, net	9	1	0	251,000	24
Net cash provided by financing activities	9	1	0	205,000	24
Net Increase (Decrease) in Cash, Cash Equivalents, and Restricted Cash	8	−12	−13	−9	10
Escrow receivable	1	—	—	—	—
Income taxes paid	2,000	2,000	2,000	2,000	2,000
Interest paid	10,000	—	—	—	—
Liability to be settled in equity	218,000	—	—	—	—
Financed insurance premium exchanged for prepaid insurance	128,000	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro